Hepatic resection for isolated stomach cancer liver metastases: A single-center experience
- Author:
Hyunyou KIM
1
;
Hyung Il SEO
Author Information
- Publication Type:Original Article
- Keywords: Liver resection; Liver metastases
- MeSH: Disease-Free Survival; Humans; Liver; Neoplasm Metastasis; Receptor, Epidermal Growth Factor; Stomach Neoplasms; Stomach
- From: Korean Journal of Clinical Oncology 2019;15(2):68-71
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The objective of this study was to investigate the outcomes of selected patients with stomach cancer liver metastasis (SCLM) without extrahepatic metastases after hepatic resection.METHODS: Patients whose imaging results did not detect extrahepatic disease were selected for hepatic resection. If R0 resection was possible and if the operative risk was low in the preoperative tests, the patients underwent hepatic resection.RESULTS: Between 2011 and 2016, seven patients underwent hepatic resection for SCLM. All patients received hepatic resection to achieve an R0 resection. Minor liver resection was performed in all patients. Two patients showed long-term survival with a single lesion and human epidermal growth factor receptor 2 (HER2)-negative tumor. The 5-year overall survival and disease-free survival rates after hepatic resection were 38.1% and 28.6%, respectively.CONCLUSION: Hepatic resection for isolated SCLM may be considered as a multimodality treatment. However, it has only limited benefits in select patients. It has long-term survival benefit in patients with single metastases and HER2-negative hormonal status.
